Watch out EpiPen there’s (another) new kid on the block. On June 15, 2017, Adamis Pharmaceuticals received FDA approval for Symjepi, their new epinephrine injection. Symjepi joins Adrenaclick, Auvi-Q, and others as an alternative to the expensive treatment for severe allergic reactions. Adamis also anticipates a low cost for the life-saving medication. As you may…

On May 16th, 2017, the FDA issued an update on canagliflozin-containing medications, like Invokana and Invokamet, as part of a year-long ongoing review. This update is the result of new data from the CANVAS and CANVAS-R clinical trials. This research showed that leg and foot amputations occurred two times more often in patients treated with…

Copyright ©2015 GoodRx, Inc. This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data…

Manufacturer Bristol-Myers Squibb has issued a voluntary recall of Eliquis, a commonly prescribed blood thinner. Eliquis can be used to reduce the risk of stroke due to atrial fibrillation, treat blood clots, prevent future blood clots, and decrease the risk of blood clots following surgery. This is a class 1 recall, the most serious type…

If you have diabetes, you’re probably no stranger to checking your own blood sugar with a little portable device known as a glucose meter. For those of you who don’t—to get a blood sugar reading, glucose meters require a small amount of blood to be placed on a test strip, and you need a new…

Back in 2010, Actemra (tocilizumab) was approved by the FDA to treat rheumatoid arthritis (RA), an inflammatory condition affecting joints. At the time, with over 1.5 million Americans suffering from RA, Actemra‘s release was promising for many doctors and patients. Actemra is a first-in-class drug, meaning it works in a new and unique way to to treat…

On March 15th, 2017, the FDA issued a drug safety communication for Viberzi (eluxadoline), which is used to treat irritable bowel syndrome with diarrhea (IBS-D). The FDA warned that Viberzi can cause an increased risk of pancreatitis in patients without a gallbladder. A review found that these patients have an increased risk of developing serious pancreatitis that can result in…

Copyright ©2015 GoodRx, Inc. This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data…

Yet another brand-name drug manufacturer is dramatically raising their prices. In recent years, we’ve seen numerous cases of manufacturers increasing brand drug prices at an astronomical rate without any reasonable explanation. The makers of life-saving drugs like EpiPen (epinephrine), Nitropress (sodium nitroprusside), and many popular insulins have dramatically increased prices, causing some patients to go…

Attention deficit/hyperactivity disorder (ADHD) is the most common behavioral disorder starting in childhood and sometimes carrying into adulthood. This disorder is characterized by inattention, hyperactivity, and impulsivity. Common treatments include medications like Adderall (amphetamine salt combo), Ritalin (methylphenidate), and Strattera (atomoxetine) – which now has a generic alternative! On May 30th, 2017 the FDA approved…